Whittier Trust Co. of Nevada »

Peregrine Pharmaceuticals shares owned by Whittier Trust Co. of Nevada

Quarter-by-quarter ownership of Peregrine Pharmaceuticals (CDMO) shares owned by Whittier Trust Co. of Nevada from 13F filings

Historical chart of Whittier Trust Co. of Nevada investment in Peregrine Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Peregrine Pharmaceuticals held by Whittier Trust Co. of Nevada consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Peregrine Pharmaceuticals by Whittier Trust Co. of Nevada

Quarter filed Position value Share count Share price at filing
2024-03-31 $23k 3.4k 6.70
2023-12-31 $22k 3.4k 6.50

More positions owned by Whittier Trust Co. of Nevada

Microsoft Corp Us Large-cap Equities (MSFT)
Apple Computer Us Large-cap Equities (AAPL)
Nvidia Corp Us Large-cap Equities (NVDA)
SPDR TR S&P 500 Etf Equity (SPY)
Amazon Us Large-cap Equities (AMZN)
Alphabet Inc Cl C Us Large-cap Equities (GOOG)
Ishares S&p 500 Index Etf Equity (IVV)
Jp Morgan Chase & Co Us Large-cap Equities (JPM)
Visa Inc Com Cl A Us Large-cap Equities (V)
Ishares S&p Midcap 400 Index Etf Equity (IJH)
Ishares Inc Core Msci Emkt Etf Equity (IEMG)
Vanguard Ftse Developed Markets Etf Equity (VEA)
Vanguard Emerging Market Equity Etf Etf Equity (VWO)
Berkshire Hathaway Inc Del Cl B Us Large-cap Equities (BRK.B)
Midcap Spdr Tr Unit Ser 1 Etf Equity (MDY)

View all positions for Whittier Trust Co. of Nevada

Top funds holding Peregrine Pharmaceuticals

Millennium Management
Vanguard Group
AltraVue Capital
Royal Bank of Canada
Palisade Capital Management
Wellington Management Company
Punch & Associates Investment Management
AWM Investment Company
Kornitzer Capital Management
New York State Common Retirement Fund
Dimensional Fund Advisors
Sargent Investment Group
Goldman Sachs Group
B. Riley Asset Management
Two Sigma Investments

View all funds holding Peregrine Pharmaceuticals